2025 MDFA research grant awards presented at Admiralty House
Next-generation gene therapy for Stargardt Disease: Enhanced AAV-mediated ABCA4 delivery to restore vision
Macular vascular disease: software standardisation and data harmonisation to accelerate the development of new imaging biomarkers and therapies
Genotype-phenotype correlations in PRPH2-associated retinal dystrophy
Nocturnal hypoxia: An unrecognised risk factor for neovascular age-related macular degeneration
Towards a personalised approach to predicting and preventing progression of age-related macular degeneration
Exploring exosomal therapeutics delivery strategies for macular disease
Reducing the risk of end-stage complications of neovascular age-related macular degeneration: macular atrophy and subretinal fibrosis
Driving into the future: strategies to enhance independence for drivers with macular degeneration, including licensing options and the role of modern vehicle technology
Macular Disease Foundation Australia (MDFA) has awarded more than $1 million to eight groundbreaking research
Macular Disease Foundation Australia today announced it has awarded more than $1 million to eight groundbreaking research projects as part of its 2025 funding round.
Macular Disease Foundation Australia (MDFA) has launched its new Research Impact Report, which showcases the groundbreaking projects our organisation has funded to help reduce the impact of macular disease.